Centre for Prognosis Studies in The Rheumatic Diseases, University Health Network, Toronto Western Hospital, 399 Bathurst St. 1E-410B, Toronto, ON M5T 2S8, Canada.
Expert Rev Pharmacoecon Outcomes Res. 2008 Apr;8(2):111-25. doi: 10.1586/14737167.8.2.111.
Adalimumab is a monoclonal antibody that inhibits TNF, an osteogenic cytokine involved in the pathogenesis of chronic, disabling inflammatory diseases. Adalimumab is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. It alleviates the symptoms of these diseases, prevents disease progression in some patients and, in the case of Crohn's disease, induces and maintains remission. Compared with traditional disease-modifying antirheumatic drugs that offer significantly less benefit, adalimumab is much more costly. However, most studies to date demonstrate the cost-effectiveness of adalimumab treatment. Cost-effectiveness data for newer indications of adalimumab, including ankylosing spondylitis and Crohn's disease, are needed. As longer term data for adalimumab become available, the cost-effectiveness data will have greater precision.
阿达木单抗是一种单克隆抗体，可抑制 TNF，后者是一种参与慢性、致残性炎症性疾病发病机制的成骨细胞细胞因子。阿达木单抗适用于类风湿关节炎、银屑病关节炎、强直性脊柱炎和克罗恩病。它可缓解这些疾病的症状，预防一些患者的疾病进展，并且在克罗恩病的情况下，诱导并维持缓解。与提供的益处明显较少的传统疾病修饰抗风湿药物相比，阿达木单抗的价格昂贵得多。然而，迄今为止的大多数研究都表明阿达木单抗治疗具有成本效益。需要阿达木单抗的新适应症（包括强直性脊柱炎和克罗恩病）的成本效益数据。随着阿达木单抗的长期数据的出现，成本效益数据将更加精确。
